For Travere Therapeutics Inc. (TVTX), the year so far has been nothing short of remarkable, with its shares hitting new highs, driven by the success of its oral kidney disease drug, Filspari.
Filspari indicated to slow kidney function decline in adults with a kidney disease called primary immunoglobulin A nephropathy, who are at risk of their disease getting worse, has been on the U.S. market since February 2023. The drug, which was approved under the accelerated approval pathway, was given full FDA approval last September. The drug is also marketed in Europe for the treatment of IgAN by the company's partner CSL Vifor.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.